Lambers Heerspink HJ - Search Results

1

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes.

Pena MJ, de Zeeuw D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, Mayer G, Rossing P, Lambers Heerspink HJ. Pena MJ, et al. Among authors: lambers heerspink hj. Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv86-95. doi: 10.1093/ndt/gfv252. Nephrol Dial Transplant. 2015. PMID: 26209743 Review.

2

Update on microalbuminuria as a biomarker in renal and cardiovascular disease.

Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D. Lambers Heerspink HJ, et al. Curr Opin Nephrol Hypertens. 2006 Nov;15(6):631-6. doi: 10.1097/01.mnh.0000247496.54882.3f. Curr Opin Nephrol Hypertens. 2006. PMID: 17053479 Review.

3

Apparent loss of urinary albumin during long-term frozen storage: HPLC vs immunonephelometry.

Brinkman JW, de Zeeuw D, Lambers Heerspink HJ, Gansevoort RT, Kema IP, de Jong PE, Bakker SJ. Brinkman JW, et al. Among authors: lambers heerspink hj. Clin Chem. 2007 Aug;53(8):1520-6. doi: 10.1373/clinchem.2007.088823. Epub 2007 Jun 15. Clin Chem. 2007. PMID: 17573417 Free article.

4

Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system.

Lambers Heerspink HJ, Witte EC, Bakker SJ, de Jong PE, de Zeeuw D, Gansevoort RT. Lambers Heerspink HJ, et al. Kidney Int. 2008 Aug;74(3):377-83. doi: 10.1038/ki.2008.186. Epub 2008 May 14. Kidney Int. 2008. PMID: 18480748 Free article.

5

Does the European clinical trials directive really improve clinical trial approval time?

Lambers Heerspink HJ, Dobre D, Hillege HL, Grobbee DE, de Zeeuw D. Lambers Heerspink HJ, et al. Br J Clin Pharmacol. 2008 Oct;66(4):546-50. doi: 10.1111/j.1365-2125.2008.03246.x. Epub 2008 Jun 28. Br J Clin Pharmacol. 2008. PMID: 18662290 Free PMC article.

6

Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality.

Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT; PREVEND Study Group. Lambers Heerspink HJ, et al. Am J Epidemiol. 2008 Oct 15;168(8):897-905. doi: 10.1093/aje/kwn209. Epub 2008 Sep 5. Am J Epidemiol. 2008. PMID: 18775924

7

Is the randomized controlled drug trial in Europe lagging behind the USA?

Lambers Heerspink HJ, Knol MJ, Tijssen RJ, van Leeuwen TN, Grobbee DE, de Zeeuw D. Lambers Heerspink HJ, et al. Br J Clin Pharmacol. 2008 Dec;66(6):774-80. doi: 10.1111/j.1365-2125.2008.03296.x. Br J Clin Pharmacol. 2008. PMID: 19032722 Free PMC article.

8

First morning voids are more reliable than spot urine samples to assess microalbuminuria.

Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R. Witte EC, et al. Among authors: lambers heerspink hj. J Am Soc Nephrol. 2009 Feb;20(2):436-43. doi: 10.1681/ASN.2008030292. Epub 2008 Dec 17. J Am Soc Nephrol. 2009. PMID: 19092125 Free PMC article.

9

Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?

de Zeeuw D, Lambers-Heerspink H. de Zeeuw D, et al. J Am Soc Nephrol. 2009 Apr;20(4):688-9. doi: 10.1681/ASN.2009020172. Epub 2009 Mar 11. J Am Soc Nephrol. 2009. PMID: 19279124 No abstract available.

10

The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.

Lambers Heerspink HJ, Agarwal R, Coyne DW, Parving HH, Ritz E, Remuzzi G, Audhya P, Amdahl MJ, Andress DL, de Zeeuw D. Lambers Heerspink HJ, et al. Am J Nephrol. 2009;30(3):280-6. doi: 10.1159/000225903. Epub 2009 Jun 15. Am J Nephrol. 2009. PMID: 19521070 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters